Evidence map›Paper›PMID 42882773›Full record

ArticleCancers2026

Tarlatamab in Small Cell Lung Cancer and Extrapulmonary Small Cell Carcinoma: A Single-Centre Retrospective Cohort Study of Routine-Practice Outcomes.

Ayrton Bangolo, Lili Zhang, Jiahe Zhao, Behzad Amoozgar, Sarvarinder Gill, Shibhani Rajanna, Shareif Abdelwahab, Andres Molina, Tanner Robinson, Umangpreet Gill and 30 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Ayrton BangoloDepartment of Hematology and Oncology, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA.ORCID 0000-0002-2133-2480
Lili ZhangDepartment of Hematology and Oncology, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA.ORCID 0000-0002-4771-4970
Jiahe ZhaoDepartment of Hematology and Oncology, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA.
Behzad AmoozgarDepartment of Bone Marrow Transplant and Cellular Therapy, Loma Linda University Health, Loma Linda, CA 92350, USA.
Sarvarinder GillDivision of Leukemia, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA.
Shibhani RajannaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Shareif AbdelwahabDepartment of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Andres MolinaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Tanner RobinsonDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Umangpreet GillDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Andrea TorresDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Akhil AkulaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Mahe TahniyatDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Maamoun SeklawiDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Tri VoDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Thilini SuriyaarachchiDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Oriana Castillo-BricenoDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Sujeewa KalubowilaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Tori SalorenzoDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Darya KlechykavaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Avery KellmanDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Kaushik RoyDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Victor H VillarrealDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Alia RamzanDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Hamza HaqDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Rajendra GuntiDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Soroush AbareshDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Gurmanjot KaurDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Jonathan MontalvoDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Zhongxuan-Jonathan WangDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Aanya SrivastavaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Lipi GudiboinaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Benjamin S FeuerDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Vennela TallaDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Rajin PersaudDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Winnie NoeDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Shalini SubramanianDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Simcha WeissmanDepartment of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Martin GutierrezDivision of Thoracic and GI Oncology and Phase 1 Clinical Trial, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA.ORCID 0000-0003-3156-3159
Miguel Gonzalez-VelezDivision of Thoracic and GI Oncology and Phase 1 Clinical Trial, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA.ORCID 0000-0001-9914-8459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTarlatamab, a Delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE), has demonstrated significant efficacy in relapsed small cell lung cancer (SCLC) in clinical trials. However, real-world clinical outcomes and its efficacy in extrapulmonary small cell carcinoma (EPSCC) remain sparsely characterized.

methodsWe conducted a retrospective, single-institution cohort study of 24 adult patients with moderately pretreated advanced SCLC (n = 19) or EPSCC (n = 5) who received standard-of-care tarlatamab. Endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.

resultsPatients had received a median of two prior lines of therapy, and 38% had baseline brain metastases. The overall intent-to-treat (ITT) ORR was 25.0%. Among response-evaluable patients (n = 18), the ORR was 33.3%. Efficacy was notably discordant between histologies: the SCLC cohort achieved an ITT ORR of 31.6% (46.2% in evaluable patients), whereas 100% of EPSCC patients experienced progressive disease. Systemic responses were observed in patients with baseline brain metastases (ORR 33.3%). The safety profile was manageable; any-grade CRS and ICANS occurred in 58% and 29% of patients, respectively. Severe (Grade ≥ 3) toxicities were rare, and tocilizumab was utilized therapeutically in 50% of patients for low-grade toxicity.

conclusionsThese real-world data are consistent with tarlatamab's systemic efficacy and tolerability in SCLC. The lack of clinical benefit observed in this small EPSCC cohort raises a hypothesis that requires prospective biomarker-correlated evaluation.

Indexed as

bispecific T-cell engagerBiTEcytokine release syndromeDLL3extrapulmonary small cell carcinomareal-world datasmall cell lung cancertarlatamab

Identifiers

PMID42882773
PMCPMC13663987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.